These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38189464)

  • 1. Dual-Dye Optical Mapping of Hearts from RyR2 R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Li Y; Yang J; Zhang R; Chen T; Zhang S; Zheng Y; Wen Q; Li T; Tan X; Lei M; Ou X
    J Vis Exp; 2023 Dec; (202):. PubMed ID: 38189464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexmedetomidine inhibited arrhythmia susceptibility to adrenergic stress in RyR2
    Li J; Luo F; Liu X; Ou X; Liu T; Huang Y; Liu W; Yang Y; Tan X; Zhou S; Chen T
    Biochem Biophys Res Commun; 2024 Aug; 720():150105. PubMed ID: 38754163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation.
    Chen B; Guo A; Gao Z; Wei S; Xie YP; Chen SR; Anderson ME; Song LS
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):841-9. PubMed ID: 22722659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine receptor-bound calmodulin is essential to protect against catecholaminergic polymorphic ventricular tachycardia.
    Nakamura Y; Yamamoto T; Kobayashi S; Tamitani M; Hamada Y; Fukui G; Xu X; Nishimura S; Kato T; Uchinoumi H; Oda T; Okuda S; Yano M
    JCI Insight; 2019 Jun; 4(11):. PubMed ID: 31167968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conduction slowing contributes to spontaneous ventricular arrhythmias in intrinsically active murine RyR2-P2328S hearts.
    Zhang Y; Wu J; Jeevaratnam K; King JH; Guzadhur L; Ren X; Grace AA; Lei M; Huang CL; Fraser JA
    J Cardiovasc Electrophysiol; 2013 Feb; 24(2):210-8. PubMed ID: 23131176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Cerrone M; Noujaim SF; Tolkacheva EG; Talkachou A; O'Connell R; Berenfeld O; Anumonwo J; Pandit SV; Vikstrom K; Napolitano C; Priori SG; Jalife J
    Circ Res; 2007 Nov; 101(10):1039-48. PubMed ID: 17872467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts.
    Zhong X; Sun B; Vallmitjana A; Mi T; Guo W; Ni M; Wang R; Guo A; Duff HJ; Gillis AM; Song LS; Hove-Madsen L; Benitez R; Chen SR
    Biochem J; 2016 Nov; 473(21):3951-3964. PubMed ID: 27582498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
    Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts.
    Goddard CA; Ghais NS; Zhang Y; Williams AJ; Colledge WH; Grace AA; Huang CL
    Acta Physiol (Oxf); 2008 Oct; 194(2):123-40. PubMed ID: 18419777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
    J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
    Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
    Kobayashi S; Yano M; Uchinoumi H; Suetomi T; Susa T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Yamamoto T; Matsuzaki M
    Circ J; 2010 Nov; 74(12):2579-84. PubMed ID: 20944434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
    Liu N; Colombi B; Memmi M; Zissimopoulos S; Rizzi N; Negri S; Imbriani M; Napolitano C; Lai FA; Priori SG
    Circ Res; 2006 Aug; 99(3):292-8. PubMed ID: 16825580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein expression profiles in murine ventricles modeling catecholaminergic polymorphic ventricular tachycardia: effects of genotype and sex.
    Saadeh K; Achercouk Z; Fazmin IT; Nantha Kumar N; Salvage SC; Edling CE; Huang CL; Jeevaratnam K
    Ann N Y Acad Sci; 2020 Oct; 1478(1):63-74. PubMed ID: 32713021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purkinje cell calcium dysregulation is the cellular mechanism that underlies catecholaminergic polymorphic ventricular tachycardia.
    Herron TJ; Milstein ML; Anumonwo J; Priori SG; Jalife J
    Heart Rhythm; 2010 Aug; 7(8):1122-8. PubMed ID: 20538074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.